DEDHAM, Mass., June 13 /PRNewswire/ -- Signet Laboratories, Inc., a
leading medical diagnostics/research company specializing in the
development of monoclonal antibodies and diagnostic assays for cancer,
infectious disease, and neurodegenerative disease, today announced the
availability of two new monoclonal antibodies L1 clone 14.10 and PTEN clone
6H2.1
The mouse monoclonal anti-L1 clone 14.10 recognizes the L1 protein
(CD171), a transmembrane protein that belongs to the immunoglobulin
supergene family. Data indicate that L1 may be overexpressed in a variety
of carcinomas. Studies have implicated L1 as a marker of unfavorable
prognosis in a variety of malignancies.
Clone 6H2.1 recognizes PTEN (phosphatase and tensin homolog), a tumor
suppressor protein that is encoded by a gene located on chromosome 10. PTEN
mutations have been observed in a wide range of cancers.
The addition of L1 and PTEN complements Signet's current product
offerings for cancer research. Signet's product portfolio includes markers
such as D2- 40, Cyclin D1, Cyclin E, HE4 and Hepsin.
Covance Announces the Acquisition of Signet Laboratories
Covance Research Products is pleased to announce that it has acquired
substantially all of the assets of Signet Laboratories, Inc. Signet, which
is based in Dedham, MA, is a leading provider of monoclonal antibodies used
in the research of cancer, infectious disease, and neurodegenerative
disease.
Signet was created in 1989 as a commercial spinout of Johnson &
Johnson's Cambridge Research Laboratories, Inc. (CRL, Cambridge, MA). The
Company was founded to continue the mission originally established at CRL
-- the early detection and recurrence monitoring of patients with cancer
and infectious disease. Signet has developed patented technology for
diagnosis and recurrence monitoring and for risk assessment of asymptomatic
patients in these areas. For more than a decade, the Company has
aggressively maintained licensing and development programs, which are
responsible for its broad patent and intellectual estate.
Covance is a leading provider of innovative antibody products and a
full range of immunology services including vaccine research & development
and preclinical vaccine testing in multiple animal models. We also provide
purpose-bred research animals (SPF rabbits, canines, and nonhuman primates)
and surgical services, including vascular access ports and telemetry
implants.
AAALACi Accredited, GLP Studies, OLAW Assured, USDA Research Registered,
and USDA Breeder Licensed
Covance Research Products
180 Rustcraft Road
Dedham, MA 02026
Phone: 800/223-0796
Fax: 781-461-2456
http://www.signetlabs.com
http://www.CRPinc.com
Contact name:
Colleen Scott
Email cscott@signetlabs.com
SOURCE Covance Research Products
 back to top
Related links:
http://www.CRPinc.com
http://www.signetlabs.com
CONTACT:
Colleen Scott of Covance Research Products,
cscott@signetlabs.com
|
